Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial.

Open forum infectious diseases

Mulligan MJ, Bernstein DI, Frey S, Winokur P, Rouphael N, Dickey M, Edupuganti S, Spearman P, Anderson E, Graham I, Noah DL, Mangal B, Kim S, Hill H, Whitaker J, Emery W, Beck A, Stephens K, Hartwell B, Ogilvie M, Rimann N, Osinski E, Destefano E, Gajadhar T, Strudwick A, Pierce K, Lai L, Yue L, Wang D, Ying C, Cline A, Foltz T, Wagner N, Dull G, Pacatte T, Taggart B, Johnson V, Haller L, Looney C, Li S, May M, Myers B, May R, Parker L, Cochran N, Bowen D, Bell M, Scoggins J, Burns A, Stablein C, Wolff M, Jolles B, Leung B, Lambert L, Shorer S, Buchanan W, Murray S, Chang S, Gorman R.
PMID: 25734170
Open Forum Infect Dis. 2014 Nov 18;1(3):ofu102. doi: 10.1093/ofid/ofu102. eCollection 2014 Dec.

BACKGROUND: Avian influenza A/H5N1 has threatened human health for nearly 2 decades. Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid tactic for mass vaccination will be needed if a pandemic occurs.METHODS: A multicenter, randomized, blinded...

Cite
Mulligan MJ, Bernstein DI, Frey S, et al. Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial. Open Forum Infect Dis. 2014;1(3):ofu102doi: 10.1093/ofid/ofu102.
Mulligan, M. J., Bernstein, D. I., Frey, S., Winokur, P., Rouphael, N., Dickey, M., Edupuganti, S., Spearman, P., Anderson, E., Graham, I., Noah, D. L., Mangal, B., Kim, S., Hill, H., Whitaker, J., Emery, W., Beck, A., Stephens, K., Hartwell, B., Ogilvie, M., Rimann, N., Osinski, E., Destefano, E., Gajadhar, T., Strudwick, A., Pierce, K., Lai, L., Yue, L., Wang, D., Ying, C., Cline, A., Foltz, T., Wagner, N., Dull, G., Pacatte, T., Taggart, B., Johnson, V., Haller, L., Looney, C., Li, S., May, M., Myers, B., May, R., Parker, L., Cochran, N., Bowen, D., Bell, M., Scoggins, J., Burns, A., Stablein, C., Wolff, M., Jolles, B., Leung, B., Lambert, L., Shorer, S., Buchanan, W., Murray, S., Chang, S., & Gorman, R. (2014). Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial. Open forum infectious diseases, 1(3), ofu102. https://doi.org/10.1093/ofid/ofu102
Mulligan, Mark J, et al. "Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial." Open forum infectious diseases vol. 1,3 (2014): ofu102. doi: https://doi.org/10.1093/ofid/ofu102
Mulligan MJ, Bernstein DI, Frey S, Winokur P, Rouphael N, Dickey M, Edupuganti S, Spearman P, Anderson E, Graham I, Noah DL, Mangal B, Kim S, Hill H, Whitaker J, Emery W, Beck A, Stephens K, Hartwell B, Ogilvie M, Rimann N, Osinski E, Destefano E, Gajadhar T, Strudwick A, Pierce K, Lai L, Yue L, Wang D, Ying C, Cline A, Foltz T, Wagner N, Dull G, Pacatte T, Taggart B, Johnson V, Haller L, Looney C, Li S, May M, Myers B, May R, Parker L, Cochran N, Bowen D, Bell M, Scoggins J, Burns A, Stablein C, Wolff M, Jolles B, Leung B, Lambert L, Shorer S, Buchanan W, Murray S, Chang S, Gorman R. Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial. Open Forum Infect Dis. 2014 Nov 18;1(3):ofu102. doi: 10.1093/ofid/ofu102. eCollection 2014 Dec. PMID: 25734170; PMCID: PMC4324215.
Copy Download .nbib Format: NLM
Population Pharmacokinetic-Pharmacodynamic Model of Oxfendazole in Healthy Adults in a Multiple Ascending Dose and Food Effect Study and Target Attainment Analysis.

Antimicrobial agents and chemotherapy

Bach T, Deye GA, Codd EE, Horton J, Winokur P, An G.
PMID: 34606333
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0143221. doi: 10.1128/AAC.01432-21. Epub 2021 Oct 04.

Oxfendazole is a potent veterinary antiparasitic drug undergoing development for human use to treat multiple parasitic infections. Results from two recently completed phase I clinical trials conducted in healthy adults showed that the pharmacokinetics of oxfendazole is nonlinear, affected...

Cite
Bach T, Deye GA, Codd EE, et al. Population Pharmacokinetic-Pharmacodynamic Model of Oxfendazole in Healthy Adults in a Multiple Ascending Dose and Food Effect Study and Target Attainment Analysis. Antimicrob Agents Chemother. 2021;66(1):e0143221doi: 10.1128/AAC.01432-21.
Bach, T., Deye, G. A., Codd, E. E., Horton, J., Winokur, P., & An, G. (2022). Population Pharmacokinetic-Pharmacodynamic Model of Oxfendazole in Healthy Adults in a Multiple Ascending Dose and Food Effect Study and Target Attainment Analysis. Antimicrobial agents and chemotherapy, 66(1), e0143221. https://doi.org/10.1128/AAC.01432-21
Bach, Thanh, et al. "Population Pharmacokinetic-Pharmacodynamic Model of Oxfendazole in Healthy Adults in a Multiple Ascending Dose and Food Effect Study and Target Attainment Analysis." Antimicrobial agents and chemotherapy vol. 66,1 (2022): e0143221. doi: https://doi.org/10.1128/AAC.01432-21
Bach T, Deye GA, Codd EE, Horton J, Winokur P, An G. Population Pharmacokinetic-Pharmacodynamic Model of Oxfendazole in Healthy Adults in a Multiple Ascending Dose and Food Effect Study and Target Attainment Analysis. Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0143221. doi: 10.1128/AAC.01432-21. Epub 2021 Oct 04. PMID: 34606333.
Copy Download .nbib Format: NLM
Vaccine-related major cutaneous reaction size correlates with cellular-mediated immune responses after tularaemia immunisation.

Clinical & translational immunology

Salerno-Gonçalves R, Chen WH, Mulligan MJ, Frey SE, Stapleton JT, Keitel WA, Bailey J, Sendra E, Hill H, Johnson RA, Sztein MB.
PMID: 33505681
Clin Transl Immunology. 2021 Jan 19;10(1):e1239. doi: 10.1002/cti2.1239. eCollection 2021.

METHODS: We investigated the host T-cell-mediated immune (T-CMI) responses elicited following immunisation with LVS vaccine formulated by the DynPort Vaccine Company (DVC-LVS) or the United States Army Medical Research Institute of Infectious Diseases (USAMRIID-LVS). We compared T-CMI responses prompted...

Cite
Salerno-Gonçalves R, Chen WH, Mulligan MJ, et al. Vaccine-related major cutaneous reaction size correlates with cellular-mediated immune responses after tularaemia immunisation. Clin Transl Immunology. 2021;10(1):e1239doi: 10.1002/cti2.1239.
Salerno-Gonçalves, R., Chen, W. H., Mulligan, M. J., Frey, S. E., Stapleton, J. T., Keitel, W. A., Bailey, J., Sendra, E., Hill, H., Johnson, R. A., & Sztein, M. B. (2021). Vaccine-related major cutaneous reaction size correlates with cellular-mediated immune responses after tularaemia immunisation. Clinical & translational immunology, 10(1), e1239. https://doi.org/10.1002/cti2.1239
Salerno-Gonçalves, Rosangela, et al. "Vaccine-related major cutaneous reaction size correlates with cellular-mediated immune responses after tularaemia immunisation." Clinical & translational immunology vol. 10,1 (2021): e1239. doi: https://doi.org/10.1002/cti2.1239
Salerno-Gonçalves R, Chen WH, Mulligan MJ, Frey SE, Stapleton JT, Keitel WA, Bailey J, Sendra E, Hill H, Johnson RA, Sztein MB. Vaccine-related major cutaneous reaction size correlates with cellular-mediated immune responses after tularaemia immunisation. Clin Transl Immunology. 2021 Jan 19;10(1):e1239. doi: 10.1002/cti2.1239. eCollection 2021. PMID: 33505681; PMCID: PMC7814273.
Copy Download .nbib Format: NLM
Showing 1 to 3 of 3 entries